Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DICIT: Diclofenac Added to Ongoing PD-1 Inhibitor in Metastatic Melanoma
2023-504191-26-00Phase 3Authorised
- Sponsor
- Universitätsklinikum Regensburg
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of diclofenac in melanoma, sponsored by Universitätsklinikum Regensburg. Primary endpoint: Objective response at week 9. Planned start Feb 2024; status: authorised.
02
Drugs
diclofenac
03
Conditions
melanoma
Beyond the preview
Go deeper on 2023-504191-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504191-26-00.